reports
Edison issues update on The Biotech Growth Trust (BIOG): Onwards and u...
Edison Investment Research Limited Edison issues update on The Biotech Growth Trust (BIOG): Onwards and upwards for performance recovery 20-March-2024 / 09:09 GMT/BST The issuer is solely responsible for the content of this announcement. London, UK, 20 March 2024 Edison issues update on The Biotech Growth Trust (BIOG): Onwards and upwards for performance recovery The Biotech Growth Trust’s (BIOG’s) two co-managers, Geoff Hsu and Josh Golomb, at global healthcare specialist OrbiMed, believe that now could be an opportune time to consider the biotech sector as it is recover...
- Pedro Fonseca
The Biotech Growth Trust - Onwards and upwards for performance recover...
The Biotech Growth Trust’s (BIOG’s) two co-managers, Geoff Hsu and Josh Golomb, at global healthcare specialist OrbiMed, believe that now could be an opportune time to consider the biotech sector as it is recovering from the longest and largest absolute and relative drawdown since 2006. The sector was negatively affected by sharply rising interest rates rather than a deterioration in industry fundamentals; indeed, the managers continue to refer to a ‘golden era’ of innovation within the biotech ...
Biotech Growth Trust: 1 director
A director at Biotech Growth Trust bought 5,000 shares at 969p and the significance rating of the trade was 54/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearl...
The Biotech Growth Trust: Historic low sector valuations
Edison Investment Research Limited The Biotech Growth Trust: Historic low sector valuations 09-Oct-2023 / 07:15 GMT/BST The issuer is solely responsible for the content of this announcement. London, UK, 9 October 2023 The Biotech Growth Trust: Historic low sector valuations The Biotech Growth Trust (BIOG) now has two co-managers, Geoff Hsu and Josh Golomb, at global healthcare specialist OrbiMed Capital. The trust has experienced a difficult period of relative performance due to the managers’ approach of focusing on emerging (smaller-cap) biotech stocks rather than large-...
- Pedro Fonseca
The Biotech Growth Trust - Historic low sector valuations
The Biotech Growth Trust (BIOG) now has two co-managers, Geoff Hsu and Josh Golomb, at global healthcare specialist OrbiMed Capital. The trust has experienced a difficult period of relative performance due to the managers’ approach of focusing on emerging (smaller-cap) biotech stocks rather than large-cap biotech businesses, because of their higher growth prospects. This strategy has been out of favour in an uncertain macroeconomic environment. Hsu and Golomb highlight attractive valuations in t...
- Pedro Fonseca
The Biotech Growth Trust - Keeping the faith in smaller-cap biotech st...
The Biotech Growth Trust (BIOG) has been managed by global healthcare specialist OrbiMed Capital since May 2005. During its tenure, the trust has outperformed its benchmark, the NASDAQ Biotechnology Index. OrbiMed favours the prospects for emerging (smaller-cap) biotech stocks rather than large-cap biotech businesses, as this is where the most industry innovation occurs. BIOG’s manager, Geoff Hsu, considers innovation to be the most important driver of the biotech sector’s long-term positive per...
- Pedro Fonseca
The Biotech Growth Trust - No style drift, sticking to long-term winni...
The Biotech Growth Trust (BIOG) is managed by global healthcare specialist OrbiMed Capital. Despite a reversal in the trust’s relative performance following a very successful FY21 (ending 31 March 2021), manager Geoff Hsu is continuing to favour smaller-cap, emerging biotech stocks, as he says these companies are where the bulk of industry innovation occurs, and this is the primary driver of the biotech sector’s long-term positive performance. The manager believes that the latest drawdown in bio...
- Pedro Fonseca
The Biotech Growth Trust - Manager expects a reversal of recent result...
The Biotech Growth Trust (BIOG) is managed by Geoff Hsu at healthcare specialist OrbiMed Capital, and benefits from OrbiMed’s presence in 11 offices across the globe. While the trust has had a weak period of absolute and relative performance over the last 12 months, the manager believes that the focus on emerging biotech (smaller-cap) and emerging market biotech stocks is the correct strategy; following this approach proved very successful for BIOG’s FY21 results. Investors are currently not foc...
- Pedro Fonseca
The Biotech Growth Trust - Performance setback may provide an opportun...
The Biotech Growth Trust (BIOG) is managed by Geoff Hsu of OrbiMed Capital, which is a specialist healthcare investor with 11 offices across the globe including in Hong Kong and Shanghai. The manager remains very positive on the outlook for the biotech sector primarily due to the current elevated level of industry innovation that he refers to as a ‘golden era’; the number of late-stage pipeline products increased by 50% between 2015 and 2020. He also believes that biotech stocks will be supporte...
- Pedro Fonseca
The Biotech Growth Trust - Performance setback may provide an opportun...
The Biotech Growth Trust (BIOG) is managed by Geoff Hsu of OrbiMed Capital, which is a specialist healthcare investor with 11 offices across the globe including in Hong Kong and Shanghai. The manager remains very positive on the outlook for the biotech sector primarily due to the current elevated level of industry innovation that he refers to as a ‘golden era’; the number of late-stage pipeline products increased by 50% between 2015 and 2020. He also believes that biotech stocks will be supporte...
- Pedro Fonseca
The Biotech Growth Trust - Favourable industry fundamentals
The Biotech Growth Trust (BIOG) generated another year of positive absolute and relative performance in 2020. Manager Geoff Hsu of global specialist healthcare investor OrbiMed Capital remains constructive on the outlook for biotech stocks, although he is mindful about the extended bull run in the US stock market. The manager is particularly encouraged by the high levels of biotech industry innovation; he believes that the favourable regulatory environment will continue and does not consider hea...
- Pedro Fonseca
The Biotech Growth Trust - Firing on all cylinders
The Biotech Growth Trust (BIOG) is managed by Geoff Hsu, who is able to draw on the considerable resources of specialist healthcare investor OrbiMed Capital. While biotech stocks have rallied strongly following the coronavirus-led stock market sell-off earlier in 2020, the manager believes they could have further to go. He is confident that a successful COVID-19 vaccine will be developed and positive fundamentals are supportive for the biotech sector’s future performance. Repositioning of BIOG...
- Pedro Fonseca
The Biotech Growth Trust - Positive outlook for 2020
The Biotech Growth Trust (BIOG) is managed by Geoff Hsu and Richard Klemm at OrbiMed Capital. They remain optimistic about the prospects for the sector in 2020 due to high levels of innovation and a relaxed regulatory environment, while a continuation in merger and acquisition (M&A) activity would also likely provide further support for biotech shares. The managers are very encouraged by the trust’s much-improved investment performance in recent months, noting they are being rewarded by the ma...
- Mel Jenner
The Biotech Growth Trust - Bright start to 2019
The Biotech Growth Trust (BIOG) is managed by Geoff Hsu and Richard Klemm of OrbiMed Capital and aims to generate long-term capital growth from a diversified portfolio of global biotech equities. Investment performance has improved markedly in 2019, following a tough few years, and the managers retain their record of long-term outperformance versus the NASDAQ Biotechnology index. They remain very optimistic on the prospects for the global biotech sector, citing a favourable regulatory environmen...
- Mel Jenner
The Biotech Growth Trust - Industry backdrop remains favourable
The Biotech Growth Trust (BIOG) is managed by Geoff Hsu and Richard Klemm at OrbiMed Capital, one of the leading global healthcare asset managers. The year 2018 proved to be tough for the trust’s performance as biotech companies delivering negative news were heavily penalised, while those delivering good news went unrewarded. However, the managers are optimistic about BIOG’s prospects. They cite a rich industry innovation pipeline that includes a series of technologies with multi-billion-dol...
- Mel Jenner
The Biotech Growth Trust - Reasons to be optimistic
The Biotech Growth Trust (BIOG) is managed by Geoff Hsu and Richard Klemm of OrbiMed Capital. They aim to generate long-term capital growth from a diversified portfolio of global biotech equities. The managers are very optimistic on the industry outlook, citing a more benign political environment, a high level of innovation, a favourable regulatory regime, and reasonable valuations. In addition, following US tax reform, they expect an acceleration in merger and acquisition activity, which has hi...
- Mel Jenner
Celebrating its 20th birthday
The Biotech Growth Trust (BIOG) was launched in 1997, aiming to generate long-term capital growth from a global portfolio of biotech stocks. Since 2005, the trust has been managed by OrbiMed Capital, the largest global specialist healthcare investor; over this period, BIOG has significantly outperformed its benchmark NASDAQ Biotech Index (sterling adjusted), despite less compelling short-term performance. The trust’s managers are bullish on the outlook for the biotech industry due to continued i...
- Mel Jenner
Industry fundamentals remain positive
The Biotech Growth Trust (BIOG) is a specialist vehicle, aiming to generate long-term capital growth via investment in global biotech stocks. Following a particularly volatile period for the biotech industry, where concerns about drug pricing and investor risk aversion have weighed heavily on stock prices, the managers are hopeful that greater clarity regarding US healthcare policy will lead to continued improved performance of biotech stocks. Industry fundamentals remain attractive, including c...
Ford Equity International Rating and Forecast Report
Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind...
Review: Positive industry fundamentals
The Biotech Growth Trust (BIOG) is a specialist investment trust that aims to generate capital growth from a portfolio of global biotech stocks. The fund is concentrated, currently holding 32 positions invested across the market capitalisation spectrum. Over the last 12 months, the industry has been volatile following controversy over US drug pricing and heightened risk aversion. However, the managers believe that industry fundamentals remain intact and companies that develop novel treatments wi...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.